Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on June 7, 2013.
- Share Price: The transaction price was $51.71 per ADS.
- Beneficiary: Dr. K. Slaoui (Connected Person) received an increase of 5 ADSs.
- Director Activity: Dr. M. Slaoui (Director/PDMR) had no change in ADS allocation (-).
- Plan Context: The change resulted from a revaluation of the cash element held notionally in GSK ADSs within the 401K plan.